摘要
Abstract
Objective To explore the therapeutic effect of Vericiguat on patients with heart failure with reduced ejection frac‑tion(HFmrEF).Methods A total of 80 HFmrEF patients admitted to Xinjiang Uygur Autonomous Regional Corps Hospital of Chi‑nese People's Armed Police Force from March 2023 to June 2024 were selected and randomly divided into a control group and an ob‑servation group,with 40 cases in each group.The control group received standard treatment,while the observation group was treated with Vericiguat tablets on the basis of the control group,and both groups were followed up for 6 months.NT‑proBNP,LVEF,LAD,LVESD,LVEDD,6MWDand Minnesota Heart Failure Quality of Life Questionnaire(MLHFQ)scores were compared.The levels of hypersensitive C‑rective protein(hs‑CRP)and Interleukin 6(IL‑6)were compared between the two groups,and the incidence of heart failure aggravated readmission was observed.Results After treatment,compared with the control group,the levesl of NT‑proBNP,hs‑CRP and IL‑6 in the observation group were significantly lower(P<0.05),and both groups showed a decrease in LVESD and LVEDD,an increase in LVEF,a decrease in MLHFQ score,and a significant extension of 6MWD(P<0.05).The quality of life of patients improved,and the effective rate of cardiac function improvement in the observation group was higher than that of the control group(95.0％vs.77.5％,P<0.05).The difference in adverse reactions between the two groups(12.5％vs.5％,P=0.235)was not statistically significant.Conclusions Vericiguat treatment for HFmrEF patients can reduce inflammation,improve NT‑proBNP,LVESD,LVEDD,LVEF,and 6MWD,and effectively alleviate clinical symptoms.关键词
射血分数轻度降低心力衰竭/维利西呱/炎性因子Key words
heart failure with mildly reduced ejection fraction/Vericiguat/inflammatory factor分类
医药卫生
